proposed amendment to the food and drug regulations project no. 1623 schedule f 5 pages available in english and french this notification announces the availability of a letter that provides an opportunity to comment on the proposed addition of four medicinal ingredients to part i of schedule f to the food and drug regulations. description of the medicinal ingredients 1. desvenlafaxine and its salts is a serotonin and norepinephrine reuptake inhibitor that is used to treat major depression. individualized instructions and direct supervision by a practitioner are required during treatment. desvenlafaxine and its salts may cause undesirable or severe side effects at normal therapeutic dosage levels. 2. eplerenone is a newer aldosterone antagonist that is used to treat heart failure in patients who have recently had a heart attack. individualized instructions and direct supervision by a practitioner are required. the patient may also require treatment with other drugs and routine laboratory monitoring. eplerenone may cause undesirable or severe side effects at normal therapeutic dosage levels. 3. fosaprepitant and its salts is a pro-drug form of aprepitant and once administered is rapidly converted to aprepitant in the body. fosaprepitant and its salts is used for the prevention of nausea and vomiting associated with cancer treatment. fosaprepitant and its salts should be administered under the supervision of a practitioner experienced in cancer therapy. the patient may require treatment with other drugs and routine laboratory monitoring. fosaprepitant and its salts may cause undesirable or severe side effects at normal therapeutic dosage levels. 4. moclobemide is a short-acting reversible inhibitor of monoamine oxidase type a that is used to treat the symptoms of depression. individualized instructions and direct supervision by a practitioner are required during treatment. moclobemide may cause undesirable or severe side effects at normal therapeutic dosage levels. the degree of regulatory control afforded by schedule f prescription drug status coincides with the risk factors associated with each medicinal ingredient. oversight by a practitioner is necessary to ensure that appropriate risk benefit information is considered before the drug containing the medicinal ingredient is administered and that the drug therapy is properly monitored. schedule f is a list of medicinal ingredients the sale of which is controlled under sections c.01.041 to c.01.049 of the food and drug regulations. part i of schedule f lists ingredients that require a prescription for human use and for veterinary use. part ii of schedule f lists ingredients that require a prescription for human use but do not require a prescription for veterinary use if so labelled or if in a form unsuitable for human use.